ARTICLE | Clinical News

Halozyme's PEGPH20 leads to worse OS in first-line pancreatic cancer

January 19, 2018 7:59 PM UTC

Halozyme Therapeutics Inc. (NASDAQ:HALO) reported that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared with chemotherapy alone in the Phase Ib/II S1313 trial to treat previously untreated metastatic pancreatic cancer. The data were released in an abstract ahead of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

In 111 evaluable patients with newly diagnosed metastatic pancreatic cancer, 3 μg/kg PEGPH20 every two weeks plus modified FOLFIRINOX led to a median OS, the primary endpoint, of 7.6 months vs. 15.1 months for modified FOLFIRINOX alone (HR=0.48)...